Thyrocare Technologies (NSE: THYROCARE) – Profit Doubles on Strong Diagnostics Demand

Thyrocare’s Q2FY26 profit surged from ₹27 crore to ₹48 crore on the back of 22% revenue growth to ₹225 crore and a 48% EBITDA jump. The company approved a 1:2 bonus issue amid improving margins driven by preventive healthcare and digital tie-ups.​ Investment Implications: Diagnostics sector consolidation and increasing preventive-health testing volumes enhance long-term earnings visibility. Actionable Insight: The stock may attract institutional inflows; accumulation advised near ₹720 for a medium-term target of ₹850.